Recombinant Human DRAK1 (STK17A) (N-GST tag)
Catalog No : IGX-RP804
366.40€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human DRAK1 (STK17A) (N-GST tag) | ||
|---|---|---|---|
| Catalog No | IGX-RP804 | ||
| Supplier’s Catalog No | IGX-RP804 | ||
| Supplier | ImuGeX | ||
| Source antigen | Insect cells | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 83 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | DRAK1; STK17A | ||
| Grade | Highly Purified | ||
| Purity | 70% - 90% | ||
| Form | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | 70% - 90% | ||
| Description | DRAK1 (STK17A) is a member of the DAP kinase-related apoptosis-inducing protein kinase family. DRAK1 encodes an autophosphorylated nuclear protein with a protein kinase domain which has apoptosis-inducing activity. DRAK1 is capable of autophosphorylation and of phosphorylating myosin light chain as an exogenous substrate. The noncatalytic C terminus of DRAK1 is crucial for full kinase activity . DRAK1 is highly expressed in placenta, but also in heart, lung, skeletal muscle, kidney, and pancreas. DRAK1 act as a novel direct target of p53 and a modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells . | ||
Product Details
© 2020 Imugex All Rights Reserved